Relationship of telomerase activity with prognosis in patients with neuroblastoma
Öz
Purpose: The aim of this study was to investigate the effect of telomerase activity on clinical characteristics and survival of patients with neuroblastoma.
Materials and Methods: This study was carried out by examining telomerase activity in previously taken pathology preparations of 87 patients who were diagnosed with neuroblastoma between 2011 and 2019 in the Pediatric Oncology Department of Çukurova University Faculty of Medicine.
Results: Totally 87 patients, 46 males (52.9%) and 41 females (47.1%), were included in our study. Median age at the time of diagnosis was 3.0 (0.08-15) years. Twenty-three (26.4%) patients included in the study had telomerase activity, 64 (73.6%) had no telomerase activity. Overall survival (OS) of patients with telomerase activity up to 8 years were 84%, while event-free survival (EFS) was 56%. Patients without telomerase activity had a 93% OS for up to 8 years, while EFS was 70%. There was no significant relationship between patients with or without telomerase activity in terms of sex, age, stage, risk group, relapse, myc- n amplification, OS and EFS.
Conclusions: In this study, no significant difference was found between telomerase activity and clinical features and survival of neuroblastoma patients. Prospective studies involving larger numbers of patients will more clearly demonstrate the impact of telomerase activity on the prognosis of patients with neuroblastoma.
Anahtar Kelimeler
Neuroblastoma, telomerase activity, prognosis, children
Proje Numarası
TTU-2018-11287
Kaynakça
- 1. Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma In: Principles and Practice of Pediatric Oncology, Pizzo PA, Poplack D), Lippincott Williams & Wilkins, Philadelphia 2011; p.886.
- 2.Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer incident and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries, LA, Smith, MA, Gurney, JG, et al, National Cancer Institute, Bethesda, MD 1999; p.35.
- 3. Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression 2014;11:704–13.
- 4. Landuzzi L, Strippoli P, Giovanni CD, Nicoletti G, Rossi I, Tonelli R, Frabetti F, Nanni P, Bagnara GP, Lollini PL. Production of stem cell factor and ezpression of Ckit in human rhabdomtosarcoma cells: Lack of autocrine growth modulation. International Journal of Cancer 1998;78:441-5.
- 5. Greider CW, Blackburn EH. Identification of a specific telo- mere terminal transferase activity in tetrahymena extracts. Cell 1985; 43:405-13.
- 6. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW. Human telomerase RNA and telomerase activity tumor tissues. Cancer Res. 1996; 56:645-50.
- 7. Piette C, Dresse MF, Forget P, Schmitz V, Demarche M, Erpicum P, et al.Clinical evaluation of 23 children with neuroblastoma. The experience of a single institution. Rev Med Liege. 2005; 60:173–80.
- 8. Simon T. Neuroblastoma Urol Ausg A. 2005;44:543–55.
- 9. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700–4.
- 10. Hiyama E, Hiyama K, Ohtsu K, Yamaoka H, Ichikawa T, Shay JW, et al. Telomerase activity in neuroblastoma: is it a prognostic indicator of clinical behaviour? Eur J Cancer Oxf Engl 1990. 1997;33:1932–6
